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S4 Appendix to:
“A fully joint Bayesian quantitative trait locus mapping of
human protein abundance in plasma”
Further examples of pQTL loci with possible implications in
metabolic disorders
This appendix provides a general discussion on validated pQTL hits and formulates hypotheses
on their clinical relevance. We performed a meta-analysis of the DiOGenes and Ottawa clinical and
proteomic data, and found that 35 of the 88 proteins under genetic control had associations with
dyslipidemia, insulin resistance or visceral fat-related measurements at FDR 5%; these associations
should be attributable metabolic factors independently of overall adiposity, as we controlled for BMI
as a potential confounder. They are displayed as a network in Fig A and are listed in Table A. We
observed consistent directions of effects in the two cohorts (see Forest plots of Fig 5 and S9 Table for
full details). For the proteins from the SomaLogic panel, the above observations may be attributable
to the known bias of the SomaLogic assay towards proteins pertaining to inflammation and cancer
(S10 Table). However, we also found that the 88 genetically-driven proteins are significantly more
associated with the clinical variables compared with protein sets chosen randomly among all proteins
quantified by our MS and SomaLogic panels (p = 0.014); this enrichment suggests that the primary
pQTL analyses can help uncover potential proteomic biomarkers for the Metabolic Syndrome and
other obesity-related complications.
Protein Protein name Clin. SNP Chr Position LOCUS PPI pQTL valid. p-value
CADH5 Cadherin-5 L rs8176741 9 136131461 1.00 4.68× 10−30
CD209 DC-SIGN L/V rs8176741 9 136131461 1.00 7.74× 10−10
rs2519093 9 136141870 1.00 6.24× 10−26
CFAB Factor B G/L rs7772063 6 31906334 0.85 9.61× 10−4
rs641153 6 31914180 1.00 3.92× 10−12
CNTN2 CNTN2 L rs11240396 1 205205081 1.00 6.82× 10−14
CO7 C7 L rs71623870 5 40966676 0.83 4.03× 10−4
ECM1 ECM1 L/V rs34964511 1 150298015 1.00 3.77× 10−6
rs71578487 1 150340059 1.00 1.07× 10−11
rs72696900 1 150425256 0.82 1.5× 10−6
rs11802612 1 150427279 1.00 3.7× 10−6
rs35094010 1 150449557 1.00 3.76× 10−6
ESTD Esterase D L rs73193065 13 47383681 0.90 2.31× 10−15
FA12 Coagulation factor XII L/V rs55785724 5 176817583 1.00 1.34× 10−5
FA7 Coagulation Factor VII L/V rs3093233 13 113758130 1.00 3.11× 10−88
FCN2 FCN2 L/V rs3811140 9 137772111 1.00 9.66× 10−14
FCN3 Ficolin-3 L/V rs10902652 1 27558522 1.00 1.62× 10−3
FETUA a2-HS-Glycoprotein G rs2593813 3 186332571 1.00 2.47× 10−10
rs2593813 3 186332571 1.00 4.51× 10−8
HEMO Hemopexin L rs10801560 1 196714600 1.00 2.36× 10−26
I17RA IL-17 sR G rs738035 22 17594886 1.00 1.48× 10−20
I17RB IL-17B R L/V rs35518479 3 53873814 0.76 9.98× 10−6
IDUA IDUA L/V rs10017289 4 943534 1.00 1.22× 10−11
IL18R IL-18 Ra L/V rs3836108 2 103037742 1.00 5.22× 10−26
IL1AP IL-1 R AcP G/L/V rs724608 3 190348810 1.00 8.7× 10−114
IL6RA IL-6 sRa G rs4845372 1 154415396 1.00 1.72× 10−81
ITIH3 Inter-alpha-trypsin L/V rs736408 3 52835354 0.97 1.46× 10−6
inhibitor heavy chain H3
KAIN Kallistatin L rs5511 14 95033595 1.00 9.9× 10−24
KLKB1 Prekallikrein L rs80177406 4 187166024 0.99 3.54× 10−6
KNG1 Kininogen HMW L rs1621816 3 186439173 1.00 1.44× 10−13
KYNU KYNU G/L/V rs6741488 2 143793701 1.00 3.22× 10−20
LYAM2 sE-Selectin L/V rs2519093 9 136141870 1.00 6.81× 10−62
LYSC Lysozyme L rs71094714 12 69790495 1.00 8.41× 10−19
MPRI IGF-II receptor L rs3777411 6 160476945 1.00 4.95× 10−11
PA2GA NPS-PLA2 G/L/V rs6672057 1 20293791 1.00 3.86× 10−15
PCSK7 PCSK7 L/V rs11216284 11 117003060 1.00 8.17× 10−31
PROC Protein C L/V rs141091409 20 33739915 0.43 1.66× 10−18
RARR2 TIG2 G/L/V rs1047586 7 150035459 0.96 2.39× 10−11
SIGL6 Siglec-6 L rs8101887 19 52029477 1.00 3.39× 10−14
SPRL1 SPARCL1 L/V rs7681694 4 88462729 0.99 5.70× 10−14
TXD12 TXD12 L rs13062429 3 49559485 1.00 2.26× 10−5
rs34519883 3 49575831 1.00 5.39× 10−33
WFKN2 WFKN2 G/L/V rs9303566 17 48922281 1.00 3.38× 10−11
Table A: Proteins associated with clinical parameters (Fig A) and controlled by pQTL variants.
All associations were detected at FDR < 5%. Associations with glycemic traits (fasting glucose, insulin,
HOMA-IR) are indicated by G, with total lipid traits (HDL, LDL, triglycerides, total cholesterol), by L, and





































Figure A: Associations of proteins under genetic control with clinical parameters. Network dis-
playing the associations (FDR < 5%) between protein levels and clinical variables obtained by meta-analysis,
adjusting for age, gender and BMI. The nodes representing clinical parameters are in dark grey with black
borders (fasting glucose, HDL, HOMA-IR, insulin resistance, LDL, total cholesterol, triglycerides, visceral
adiposity index), and those representing proteins are in light grey with the type of genetic control, cis or
trans, depicted with circles or squares, respectively. The edge thickness is proportional to the significance of
association, and the node size is proportional to its connectivity.
As shown in the network of Fig A, the triglyceride measurements and visceral adiposity index
(VAI) have the highest degree of connectivity and are connected with measures of insulin resistance
and other lipid traits via proteins such as FA7, IL1AP, KYNU, PROC, RARR2 and WFKN2. CFAB,
FETUA, PA2GA have lower connectivity, yet are relevant in the context of obesity [1–3]. Trans-
regulated proteins (Fig A) were also implicated in clinical associations: CADH5, CD209 and LYAM2,
all controlled by the pleiotropic locus ABO ; HEMO (Hemopexin), a liver glycoprotein controlled by
the CFH locus, itself coding for another liver glycoprotein; PROC controlled by its own receptor
PROCR; and TXD12 (thioredoxin domain containing 12), controlled by the DAG1/BSN locus.
In the subsequent sections, we expand on the possible functional and biomedical relevance of
several representative examples of pQTL associations in the context of obesity complications. Unless
otherwise specified, all associations described have meta-analysis FDR corrected p-value below 5%,
and we provide their nominal p-values in parentheses.
Clinical associations with proteins controlled by the pleiotropic locus ABO
Our clinical analyses indicated associations of CD209 and LYAM2 with triglycerides and visceral fat,
and CADH5 with triglycerides only (Fig 5). The LYAM2 levels were associated with all the glycemic
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Figure B: Correlation between CD209 and other macrophage protein levels. Pearson correla-
tion coefficient with 95% confidence interval for the association between CD209 protein levels (controlled by
rs8176741, see Results section) and M1-M2 macrophage protein levels in Ottawa and in DiOGenes.
HOMA-IR: p = 1.8× 10−4), but only with fasting glucose in the DiOGenes cohort (p = 8.91× 10−4),
although we observed a trend for HOMA-IR (nominal p = 0.02, corrected p = 0.15). Since the Ottawa
subjects are more insulin-resistant than the DiOGenes subjects (average HOMA-IR with standard
deviation: 4.97(3.88) versus 3.00(1.71), p = 2.52 × 10−18; S1 Table), LYAM2 might represent a
marker of insulin-resistance severity. Consistent with this hypothesis, the plasma levels of LYAM2 are
employed as a biomarkers of endothelial dysfunction and risk of type 2 diabetes [4].
We found that CD209 circulating levels were positively associated with HDL, negatively with
triglyceride levels, and, consistently with these effects, negatively with visceral fat index (Fig 5),
suggesting beneficial effects of high CD209 levels. Further investigation using deconvolution of adipose
tissue gene expression profiles showed that CD209 is predominantly secreted by M2 macrophages
[5]. These cells are involved in extracellular matrix remodelling and secrete cytokines with an anti-
inflammatory role, counteracting the effect from pro-inflammatory macrophages M1. Interestingly,
other adipose cell types, including M1 macrophages display little, if any, CD209 expression. M1 and
M2 macrophages have been extensively discussed in the context of obesity, and it is well established
that M2 macrophages have a protective role against obesity and insulin resistance [6] and increase fatty
oxidation and oxidative phosphorylation [7]. In our data (both the Diogenes and Ottawa cohorts, and
at FDR 5%), we found that CD209 levels were positively correlated with M2 secreted proteins (IL10,
CSF1, ARGI1) and negatively correlated with M1 pro-inflammatory markers, such as TGF-beta, IL6
and interferon-gamma (Fig B).
Importantly, CD209 was positively associated with circulating levels of adiponectin, an hormone
secreted in adipose tissue which plays a key role in glucose regulation, fatty acid oxidation and
triglycerides clearance. This lends support that CD209 could be a secreted protein, released by
M2 macrophages from adipose tissue, with a beneficial role in controlling lipid levels, thereby possibly
protecting from developing dyslipidemia and related metabolic complications.
Clinical associations with the XRCC6 protein levels
We observed significant associations between the XRCC6 protein levels and several clinical variables
in the Ottawa cohort (FDR < 5%). Higher expression was associated with decreased HDL (p =
5.83 × 10−4), as well as with higher triglycerides (p = 4.39 × 10−4), insulin levels (p = 4.50 × 10−4)
and visceral adiposity (p = 5.94 × 10−5; Fig 5). We only found marginal associations using the
DiOGenes data for insulin levels (nominal p = 0.02, corrected p = 0.14) and HOMA-IR (nominal
p = 0.02, corrected p = 0.16). The directionality of these effects was consistent in both cohorts. As
the Ottawa subjects were more severely obese, the effects might be larger for subjects with pronounced
Metabolic Syndrome.
Our pQTL sentinel SNP, rs4756623, is intronic and located within the LRRC4C gene, a binding
partner for Netrin G1 and member of the axon guidance [8]. To our knowledge, LRRC4C has not
been previously described in the context of obesity, insulin resistance or type 2 diabetes. However,
its partner Netrin G1 is known to promote adipose tissue macrophage retention, inflammation and
insulin resistance in obese mice [9]. The underlying regulatory mechanisms between rs4756623 and
the XRCC6 locus should be clarified, and functional studies will be required to understand their
physiological impact.
CFAB and RARR2, mediators of adipogenesis are under genetic control
CFAB (complement factor B) and RARR2 (Retinoic acid receptor responder protein 2) levels associate
with distinct clinical parameters (Figs A and 5), yet both play a role in adipogenesis and hence are
particularly interesting in the context of obesity and related co-morbidities.
The CFAB protein controls the maturation of adipocytes in rat [1] and has a determinant role in
metabolic and cardiovascular dysfunctions linked with the Metabolic Syndrome [10]. In our study, both
the MS and SomaLogic measurements were positively associated with BMI (MS: p = 2.08 × 10−8,
SomaLogic: p = 2.23 × 10−13) and with fasting insulin (adjusting for BMI; MS: p = 4.45 × 10−5,
SomaLogic: p = 3.44×10−4). The CFAB SomaLogic levels were negatively associated with cholesterol
(p = 1.43× 10−3), LDL (p = 1.30× 10−5), and with HDL at higher FDR (nominal p = 1.47× 10−2,
corrected p = 0.11). This is consistent with previous work linking CFB gene expression from different
human adipose tissue fractions with insulin resistance and lipid levels [11].
Our MS and SomaLogic analyses independently highlighted the same cis-acting locus as putative
regulator of the CFAB protein. In particular, the sentinel pQTL SNP detected in the SomaLogic
analysis, rs641153, is a missense variant located in the MHC region, 180 base pairs away from a
transcription binding site (significantly closer than other SNPs, p = 1.16×10−2). Further investigation
using JASPAR [12] and SNP2TFBS [13]indicated that rs641153 may affect the binding sites of four
transcription factors (EBF1, TFAP2A, TFAP2C and HNFA), and this SNP has indeed been reported
as both e- and pQTL [14, 15].
RARR2 (Chemerin protein) is encoded by an essential adipogenesis gene, RARRES2. This
adipokine plays an important role in inflammation, adipogenesis, angiogenesis and glucose homeostasis
[16, 17]. Our pQTL analyses indicated a cis association between a missense variant, rs1047586, and
RARR2 protein levels, in line with previous findings reporting this SNP as e- and pQTL (S4 and S7 Ta-
bles). Moreover, our analyses of protein levels revealed significant associations with triglycerides,
fasting insulin and HDL (Fig 5, S9 Table), which is consistent with previously described pleiotropic
associations of RARRES2 variants with circulating RARR2, triglyceride levels and diverse measure-
ments related to inflammation [18], and findings from animal models [19, 20]. Moreover, MS and
SomaLogic RARR2 levels were strongly associated with visceral fat, even when controlling for BMI
(Fig 5; S9 Table), further strengthening the relevance of this protein in the development of the
Metabolic Syndrome [17, 21].
The importance of IL1AP for Metabolic Syndrome
The IL-1 pathway plays a critical role in the immune-response associated with obesity and type 2
diabetes [22]; other IL-1 related cytokines, such as IL-1ra, are also well documented in the context of
type 1 and type 2 diabetes [23]. The IL1AP (IL-1 receptor accessory) protein is a co-receptor of the
IL-1 receptor, and its soluble levels were found reduced in obese subjects [24]. Our analyses found an
association between rs724608 and IL1AP, corroborating previously identified associations with SNPs
in LD (r2 = 0.93) [24].
We found associations between IL1AP expression and measures of fasting insulin levels (p = 3.88×
10−5), HOMA-IR (p = 3.89× 10−4), triglycerides (p = 1.61× 10−3) and visceral fat (p = 2.1× 10−4)
(Figs A and 5). Moreover, worsened Metabolic Syndrome score [25] were associated with lower protein
levels (p = 1.20× 10−3 in Ottawa and p = 2.50× 10−4 in DiOGenes).
WFKN2, a TGFβ-activity protein with protective effect against metabolic
disorders
The role of the WFKN2 protein and of its coding gene, WFIKKN2, in regulating TGFβ activity
has been extensively studied in muscle and skeletal muscle [26], but, to our knowledge, not in other
tissues. We describe it for the first time in the context of obesity and metabolic disorders. We found
that higher protein levels were associated with lower levels of fasting insulin, triglycerides, HOMA-IR
and visceral fat (Fig 5), suggesting a protective role against metabolic dysregulation.
Our analyses suggested that the WFKN2 levels are controlled by rs9303566, which is consistent
with other p- and eQTL studies (S4–S7 Tables). This SNP was found to be associated with DNA
methylation and histone marks [27, 28], and is located within 100 base pairs of a transcription factor
binding site, with numerous factors such as MYBL2, NFIC, EP300 and MXI1. It is in strong LD with
other SNPs with potential regulatory impact; for instance, it is located 9Kb upstream to rs8072476
(r2 = 0.97), which overlaps another cluster of transcription factor binding sites (FOXA1, ESR1, USF1
& 2, TFAP2A & 2C).
Inflammation mediated proteins and their role in insulin resistance
We found a cis effect of rs6741488 on KYNU (Kynureninase) plasmatic levels. KYNU is an enzyme
involved in the biosynthesis of nicotinamide adenine dinucleotide (NAD) cofactors from tryptophan.
This protein and its pathway have been found to be particularly relevant for obesity and associated
metabolic disorders. KYNU was found to be up-regulated by pro-inflammatory cytokines in human
primary adipocytes, and more so in the omental adipose tissue of obese compared to lean control
subjects [29]. Other studies indicated that the kynurenine pathway (KP) may act as an inflammatory
sensor, and that increased levels of its catabolites may be linked with several cardiometabolic defects,
including cardiovascular disease, diabetes and obesity [30]. In our cohorts, higher KYNU levels were
associated with decreased HDL levels (p = 6.66 × 10−4), and increased triglycerides levels (p =
3.43×10−8), visceral fat (p = 2.51×10−8) and insulin resistance (marginally, nominal p = 2.53×10−2,
corrected p = 0.17), see Fig 5; as expected, higher protein levels were associated with a worsened
Metabolic Syndrome score (Ottawa p = 8.23× 10−5; DiOGenes p = 3.62× 10−6).
Recent work suggested a causal link between obesity and cancer, mediated by KP activation
through inflammatory mechanisms [31]. Interestingly, our analyses highlighted two soluble interleukin
receptor antagonist proteins, namely IL6RA and I17RA, that were both under genetic control and
associated with insulin resistance (Fig A). We did not find significant correlation between the I17RA
and KYNU protein levels, but we did observe a significant negative correlation between IL6RA and
KYNU (Ottawa p = 0.01 and DiOGenes p = 4 × 10−3). We found a link between the plasma levels
of KYNU and pro-inflammatory molecules, namely, IL6, IFNG and TNFα. In the Ottawa cohort,
where subjects displayed high low-grade inflammation status, KYNU was positively associated with
IL6 and IFNG at FDR 5%, while in DiOGenes, we found a positive association with IFNG only
(see Fig C). Finally, metabolic dysfunctions mediated via KP may relate to another inflammatory
pathology, namely, psoriasis [32], a skin disease aggravated by obesity and improved by weight loss
[33, 34].
Our results thus highlighted pQTLs with probable roles in inflammation and subsequent metabolic
dysfunctions, reinforcing previous discussion [30, 35] of the potential of KP therapeutic inhibitors
























































































































































































































Figure C: Correlation of KYNU, IFNG, IL6, THFA, IL6RA, I17RA and IL1B in Ottawa (left)
and in DiOGenes (right).
Complement/coagulation: a trans-acting insertion linking PROC and its
receptor
PROC (Protein C, coding gene PROC on chromosome 2) and its paralog protein FA7 (Coagulation
Factor 7, coding gene F7 on chromosome 13) regulate the complement and the coagulation systems.
Both systems promote inflammation [36] and contribute to metabolic dysfunction in the adipose tissue
and liver [37]. Our analyses suggested novel pQTLs for these proteins (S3 Table): FA7 was associated
with rs3093233, which is a known eQTL of F7 and F10 in several tissues (S7 Table). PROC may be
controlled by trans-regulatory mechanisms, initiated in its receptor gene, PROCR, on chromosome
20; it was indeed associated with an insertion, rs141091409, located 20Kb upstream of PROCR, an
association observed with both our proteomic platforms. Previous studies found associations between
cardiovascular disease and variants located in the PROC or PROCR genes [38, 39]. Interestingly,
our hit, rs141091409, was in strong LD (r2 > 0.95) with the missense variant rs867186, previously
identified as associated with coronary heart disease [39].
Our clinical analyses support the relation of PROC and FA7 levels with lipid traits: both were
positively associated with cholesterol, triglycerides and visceral fat (Figs A and 5). PROC levels
were quantified by both platforms, and displayed consistent results. The SomaLogic measurements
of PROC were positively associated with LDL (p = 5.39 × 10−5). The role of these proteins for
cardiovascular disease and NAFLD diseases in the overweight/obese population would merit further
investigation.
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